BHCM
XFOR icon

Brevan Howard Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Brevan Howard Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-127,321
Closed -$526K – 2632
2026
Q1 		$526K Buy
+127,321
New +$477K ﹤0.01% 1278

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Brevan Howard Capital Management's XFOR Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of X4 Pharmaceuticals (XFOR) in Q2 2026, closing a stake of 127,321 shares — an estimated $526K sold.

Brevan Howard Capital Management first reported a position in XFOR in Q1 2026 and held it in 1 quarter. The position peaked at $526K in Q1 2026. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining X4 Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 127,321 X4 Pharmaceuticals shares in Q2 2026, an estimated $526K.
  • Brevan Howard Capital Management first reported a position in X4 Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's X4 Pharmaceuticals position peaked at $526K in Q1 2026.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.